UK-based biotech firm F-star has announces a collaborative agreement with the US start-up Denali Therapeutics to research and develop antibodies for the delivery of medicines across the blood-brain barrier (BBB) into the central nervous system (CNS).
Under the accord, Denali will make an upfront payment to F-star of $6 million. Denali also has the option to acquire F-star Gamma (F-star's latest asset centric vehicle) prior to the initiation of the first Phase I clinical trial in return for aggregate exercise and milestone payments to the F-star Gamma shareholders of up to $450 m in total.
If Denali does not exercise the option, it has the right it license a number of MAb based on each Fcab generated by F-star Gamma, in return for license fees, development, regulatory and commercial milestones payments with a potential aggregate value of $1 billion and tiered royalties on product sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze